title: Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies.
abstract: Conventional vaccination with the cocaine molecule conjugated to a protein carrier is a new approach in the treatment of addiction. Experimentally, this strategy has been shown to alter the pharmacokinetics as well as the psychostimulant effect of a cocaine challenge. The purpose of this study was to investigate whether a more stable and less controversial molecule, an anti-idiotypic antibody, which mimics the configuration of the cocaine molecule (Ab2beta), could be successfully used instead of cocaine. Two cocaine conjugates that presented different areas of the cocaine molecule to the immune system were used to produce monoclonal antibodies specific for cocaine (Ab1). Several anti-idiotypic antibodies were then produced. Four were identified as Ab2beta, or internal images of the antigen; when injected into BALB/c mice, they elicited an anticocaine response. The anticocaine response elicited by one of the four Ab2beta (K1-4c) was sufficient to significantly reduce the level of cocaine that targeted the brain following cocaine challenge, compared with the level of cocaine found in the brain of control animals immunized with irrelevant antibody. In conclusion, the possibility of an anti-idiotypic vaccine seems to be worth pursuing.
authors.affiliation: Departments of Pathobiology and Chemistry, University of Illinois, Urbana, IL 61802, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Schabacker
authors.forename: K S
authors.initials: KS
authors.lastname: Kirschbaum
authors.forename: M
authors.initials: M
authors.lastname: Segre
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology; D000918:Antibody Specificity; D001921:Brain / Q000378:metabolism; D003042:Cocaine / Q000276:immunology* / Q000493:pharmacokinetics; D019970:Cocaine-Related Disorders / Q000628:therapy*; D005240:Feasibility Studies; D016233:Immunotherapy, Active / Q000379:methods*; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D003042:Cocaine